TransMedics Group (TMDX) has drawn fresh attention after a recent share price swing, with the stock rising 7.6% in the latest session and gaining 14.3% over the past month despite weaker multi year returns.

At the current share price of $78.79, TransMedics Group has seen a 30 day share price return of 14.3%, but the year to date share price return is down 35.8% and the 1 year total shareholder return is down 38.2%, even though the 5 year total shareholder return remains positive at 139.9%. This points to recent pressure following a stronger longer term run.

If this kind of volatility has your attention, it can be a good moment to scan for other healthcare technology opportunities using our screener of 38 healthcare AI stocks

With TransMedics Group still well below its recent highs, but showing positive multi year returns and revenue growth, the key question for investors is whether the current valuation leaves upside on the table or if the market is already pricing in future growth.

Most Popular Narrative: 33.2% Undervalued

At $78.79 per share, the most followed narrative on TransMedics Group frames a fair value closer to $117.89, built on detailed revenue, margin and valuation assumptions discounted at 8.31%.

Expansion into new organ types (notably kidney) and next-generation product launches (Gen 3 OCS platforms for heart, lung, and liver) are expected to materially grow TransMedics' total addressable market, improve product mix, and support higher average selling prices, benefiting earnings and longer-term net margins.

Want to see what revenue path, margin profile and future earnings multiple sit behind that fair value gap? The narrative sets a detailed roadmap for how the OCS platform, new organ programs and international rollout could translate into higher cash flows and a higher implied valuation multiple over time.

Result: Fair Value of $117.89 (UNDERVALUED)

However, TransMedics Group still faces meaningful risks, including regulatory scrutiny around organ procurement practices and potential margin pressure if rising R&D and logistics costs do not translate into efficiencies.

Next Steps

Given the mixed recent performance and fair value gap around TransMedics Group, it makes sense to review the detail yourself and move quickly if your view differs. To see which potential bright spots investors are focusing on, check the 4 key rewards.

Looking for more investment ideas beyond TransMedics Group?

If TransMedics Group has sharpened your focus, do not stop there. Use the Simply Wall Street Screener to uncover other stocks that might fit your criteria.

• Spot potential mispriced opportunities by reviewing companies on the 44 high quality undervalued stocks and see which stocks currently trade below their estimated fair value.
• Prioritise strength by filtering for companies in the solid balance sheet and fundamentals stocks screener (48 results) that pair financial resilience with fundamentals you can scrutinise in detail.
• Stay ahead of the crowd by hunting for underfollowed prospects through the screener containing 19 high quality undiscovered gems before they draw wider market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.